Company / Revenue per Share
Celldex Therapeutics, Inc. Revenue per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$0.02
FY2025
5-year range
$0.02 / $0.12
FY2021-FY2025
Trend
-78.0%
vs FY2024
Sector context
#153 of 154
Health Care
What the data says
Among 154 Health Care companies, Celldex Therapeutics, Inc. is in the bottom 1% for revenue per share. Revenue per Share has fluctuated over the past 10 years, ranging from $0.01 in FY2017 to $0.73 in FY2018.
Based on SEC 10-K filings.
0.02 in FY2025 with a 5-year CAGR of -34.1%.
Declined from $0.12 to $0.02 over the past 2 years.
Health Care sector context is included.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- -22.5%
- 5-Year CAGR
- -34.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 1% in Health CareTop 99% of 154This company $0.02 Sector average $123.99
▼
-100.0% below sector average
Key checks
Key Insights
- In FY2025, revenue per share decreased 78.0% year-over-year.
- Ranks #153 out of 154 companies in the Health Care sector.
- Peak revenue per share was recorded in FY2018.
- Lowest revenue per share in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.40 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.02 | -78.0% |
| FY2024 | $0.11 | -14.1% |
| FY2023 | $0.12 | +146.7% |
| FY2022 | $0.05 | -49.8% |
| FY2021 | $0.10 | -46.9% |
| FY2020 | $0.19 | -11.0% |
| FY2019 | $0.21 | -71.4% |
| FY2018 | $0.73 | +5673.2% |
| FY2017 | $0.01 | -77.4% |
| FY2016 | $0.06 | +1.4% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026